South Korea
· Delayed Price · Currency is KRW Hyundai Bioscience Statistics
Total Valuation
Hyundai Bioscience has a market cap or net worth of KRW 728.30 billion. The enterprise value is 751.04 billion.
| Market Cap | 728.30B |
| Enterprise Value | 751.04B |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Hyundai Bioscience has 39.82 million shares outstanding. The number of shares has increased by 0.69% in one year.
| Shares Outstanding | 39.82M |
| Shares Change (YoY) | +0.69% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 0.80% |
| Owned by Institutions (%) | 6.82% |
| Float | 34.66M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 78.96 |
| PB Ratio | 14.71 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -114.26 |
| EV / Sales | 81.28 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -225.95 |
Financial Position
The company has a current ratio of 0.72, with a Debt / Equity ratio of 0.61.
| Current Ratio | 0.72 |
| Quick Ratio | 0.62 |
| Debt / Equity | 0.61 |
| Debt / EBITDA | n/a |
| Debt / FCF | -11.02 |
| Interest Coverage | -13.11 |
Financial Efficiency
Return on equity (ROE) is -23.15% and return on invested capital (ROIC) is -6.57%.
| Return on Equity (ROE) | -23.15% |
| Return on Assets (ROA) | -6.18% |
| Return on Capital (ROIC) | -6.57% |
| Revenue Per Employee | 146.66M |
| Profits Per Employee | -104.33M |
| Employee Count | 63 |
| Asset Turnover | 0.11 |
| Inventory Turnover | 3.78 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.57% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -31.57% |
| 50-Day Moving Average | 19,479.20 |
| 200-Day Moving Average | 20,594.00 |
| Relative Strength Index (RSI) | 37.82 |
| Average Volume (20 Days) | 191,374 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Hyundai Bioscience had revenue of KRW 9.24 billion and -6.57 billion in losses. Loss per share was -165.25.
| Revenue | 9.24B |
| Gross Profit | 4.09B |
| Operating Income | -8.30B |
| Pretax Income | -13.27B |
| Net Income | -6.57B |
| EBITDA | -7.29B |
| EBIT | -8.30B |
| Loss Per Share | -165.25 |
Balance Sheet
The company has 24.93 billion in cash and 36.63 billion in debt, giving a net cash position of -11.71 billion or -294.04 per share.
| Cash & Cash Equivalents | 24.93B |
| Total Debt | 36.63B |
| Net Cash | -11.71B |
| Net Cash Per Share | -294.04 |
| Equity (Book Value) | 60.53B |
| Book Value Per Share | 1,242.99 |
| Working Capital | -11.73B |
Cash Flow
In the last 12 months, operating cash flow was -3.19 billion and capital expenditures -130.21 million, giving a free cash flow of -3.32 billion.
| Operating Cash Flow | -3.19B |
| Capital Expenditures | -130.21M |
| Free Cash Flow | -3.32B |
| FCF Per Share | -83.48 |
Margins
Gross margin is 44.24%, with operating and profit margins of -89.84% and -71.14%.
| Gross Margin | 44.24% |
| Operating Margin | -89.84% |
| Pretax Margin | -143.57% |
| Profit Margin | -71.14% |
| EBITDA Margin | -78.94% |
| EBIT Margin | -89.84% |
| FCF Margin | -35.97% |
Dividends & Yields
Hyundai Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.69% |
| Shareholder Yield | -0.69% |
| Earnings Yield | -0.90% |
| FCF Yield | -0.46% |
Stock Splits
The last stock split was on December 16, 2011. It was a reverse split with a ratio of 0.1.
| Last Split Date | Dec 16, 2011 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Hyundai Bioscience has an Altman Z-Score of 12.56.
| Altman Z-Score | 12.56 |
| Piotroski F-Score | n/a |